Published in BMC Biotechnol on March 01, 2015
Comparison of Three Escherichia coli Strains in Recombinant Production of Reteplase. Avicenna J Med Biotechnol (2016) 0.77
Functionally Expression of Metalloproteinase in Taenia solium Metacestode and Its Evaluation for Serodiagnosis of Cysticercosis. Iran J Parasitol (2016) 0.75
Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol (1986) 55.34
Protein production by auto-induction in high density shaking cultures. Protein Expr Purif (2005) 29.74
Rapid protein-folding assay using green fluorescent protein. Nat Biotechnol (1999) 6.98
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature (1983) 5.27
A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med (1978) 3.92
Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm. Proc Natl Acad Sci U S A (1999) 3.60
Controlling basal expression in an inducible T7 expression system by blocking the target T7 promoter with lac repressor. J Mol Biol (1991) 2.66
Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. Nat Struct Biol (2002) 2.60
Spontaneous cAMP-dependent derepression of gene expression in stationary phase plays a role in recombinant expression instability. Gene (1998) 2.03
Molecular mechanism for dimerization to regulate the catalytic activity of human cytomegalovirus protease. Nat Struct Biol (2001) 1.64
Expression of active human tissue-type plasminogen activator in Escherichia coli. Appl Environ Microbiol (1998) 1.47
Unconventional serine proteases: variations on the catalytic Ser/His/Asp triad configuration. Protein Sci (2008) 1.44
Overcoming codon bias: a method for high-level overexpression of Plasmodium and other AT-rich parasite genes in Escherichia coli. Int J Parasitol (2000) 1.32
The herpesvirus proteases as targets for antiviral chemotherapy. Antivir Chem Chemother (2000) 1.21
Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum Mol Genet (2003) 1.14
Strategies for the improvement of thrombolytic agents. Thromb Haemost (1991) 1.10
Tissue-type plasminogen activator: characteristics, applications and production technology. Biotechnol Adv (1996) 1.04
The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood (1992) 1.03
Secretion of active kringle-2-serine protease in Escherichia coli. Biochemistry (1990) 1.00
The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol (2009) 0.99
Simple defined autoinduction medium for high-level recombinant protein production using T7-based Escherichia coli expression systems. Appl Microbiol Biotechnol (2011) 0.99
Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharmacol Exp Ther (1984) 0.96
Structural insight into serine protease Rv3671c that Protects M. tuberculosis from oxidative and acidic stress. Structure (2010) 0.95
Interaction of thrombin with sucrose octasulfate. Biochemistry (2011) 0.95
Secretion of active recombinant human tissue plasminogen activator derivatives in Escherichia coli. Appl Environ Microbiol (2001) 0.95
The production of improved tissue-type plasminogen activator in Escherichia coli. Semin Thromb Hemost (2001) 0.86
Integrin-specific tissue-type plasminogen activator engineered by introduction of the Arg-Gly-Asp sequence. Biochem Biophys Res Commun (1996) 0.85
Role of P225 and the C136-C201 disulfide bond in tissue plasminogen activator. Protein Sci (1998) 0.85
Production of soluble single-chain T-cell receptor fragments in Escherichia coli trxB mutants. Mol Immunol (1998) 0.84
Functional properties of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli. J Biol Chem (1990) 0.82
Cloning, purification and biochemical characterization of a thrombus-ditargeting thrombolytic agent, comprised of annexin B1, ScuPA-32K and fibrin-adherent peptide. J Biotechnol (2006) 0.81
Expression of active recombinant human tissue-type plasminogen activator by using in vivo polyhydroxybutyrate granule display. Appl Environ Microbiol (2010) 0.80
The crystal structure of hexamer RraA from Pseudomonas aeruginosa reveals six conserved protein-protein interaction sites. Protein J (2010) 0.80
Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding. Biochim Biophys Acta (2001) 0.79
Renaturation and purification of recombinant tissue-type plasminogen activator expressed in E. coli. Biochem Mol Biol Int (1997) 0.77